

UNITED THERAPEUTICS CORP

Form 8-K

January 26, 2004

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15 (d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 26, 2004

United Therapeutics Corporation

---

(Exact Name of Registrant as Specified in Charter)

---

Delaware

---

000-26301

---

52-1984749

(State or Other  
Jurisdiction of  
Incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification Number)

---

1110 Spring Street  
Silver Spring, MD

---

20910

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code:

(301) 608-9292

---

**Item 5. Other Events.**

On January 26, 2004, United Therapeutics Corporation issued a press release announcing (i) the bioequivalence of Remodulin when delivered intravenously as compared to subcutaneous delivery, and (ii) no net patient growth in the fourth quarter of 2003 due to higher patient discontinuations and the year-end holiday slow down in new patient starts.

**Item 7. Exhibits**

(c) Exhibits

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99	Press release dated January 26, 2004

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

UNITED THERAPEUTICS CORPORATION

Dated: January 26, 2004

By: /s/ Paul A. Mahon  
Name: Paul A. Mahon  
Title: EVP and General Counsel

---

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99	Press Release dated January 26, 2004